Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 67 clinical trials
Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

The primary aims of this study is to determine the efficacy and tolerability of Extracorporeal Photopheresis (ECP) for the treatment of either refractory (240) or newly diagnosed (400-450) Bronchiolitis Obliterans Syndrome (BOS) in patients after lung transplantation.In compliance with the Centers for Medicare and Medicaid Services' (CMS) Coverage with Evidence …

  • 5 views
  • 21 Jul, 2021
  • 22 locations
Prednisone in Cystic Fibrosis Pulmonary Exacerbations

adjunctive therapy for pulmonary exacerbations in CF patients who have not recovered their baseline forced expiratory volume in 1 second (FEV1) after 7 days of IV antibiotic treatment. The primary outcome

  • 32 views
  • 19 Jun, 2021
  • 12 locations
Pectoralis and Serratus Muscle Blocks

The overall research plan is PECS/SAP blocks with liposomal bupivacaine improve the Overall Benefit Analgesia Score averaged over the postoperative days 1, 2, and 3. A 2-point reduction in OBAS will be considered the minimal clinically important benefit.

  • 0 views
  • 28 Jan, 2021
  • 1 location
Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial

Large population-based studies suggest that patients with chronic obstructive pulmonary disease (COPD) are 2 to 3 times at risk for cardiovascular mortality, which accounts for a large proportion of the total number of deaths. How COPD increases the risk of poor cardiovascular outcomes is largely unknown. However, there is growing …

fluticasone
cigarette smoke
bronchodilator
corticosteroids
  • 130 views
  • 07 Nov, 2020
  • 9 locations
Additional Minocycline Pleurodesis After Thoracoscopic Procedures for Primary Spontaneous Pneumothorax

To test if additional minocycline pleurodesis after thoracoscopic procedures can reduce the rates of ipsilateral recurrence for patients with primary spontaneous pneumothorax.

hemopneumothorax
spontaneous pneumothorax
minocycline
pleurodesis
vats
  • 0 views
  • 07 Nov, 2020
  • 1 location
Intrapleural Minocycline After Simple Aspiration for the Prevention of Primary Spontaneous Pneumothorax

The estimated recurrence rate of primary spontaneous pneumothorax is 23-50% after the first episode, and the optimal treatment remains unknown. In the recently published British Thoracic Society (BTS) guidelines, simple aspiration is recommended as first line treatment for all primary pneumothoraces requiring intervention. However, the 1 year recurrence rate of …

spontaneous pneumothorax
cavity
minocycline
thoracoscopy
aspiration
  • 2 views
  • 07 Nov, 2020
Pivotal Study to Assess the Efficacy Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

>Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo Health related quality of life, assessed by the change from baseline to Week 52 in the St

eosinophil count
corticosteroids
copd exacerbation
antibiotics
forced expiratory volume
  • 1146 views
  • 14 Jun, 2021
  • 454 locations
Pivotal Study to Assess the Efficacy Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

>Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo Health related quality of life, assessed by the change from baseline to Week 52 in the St

eosinophil count
corticosteroids
copd exacerbation
forced expiratory volume
severe chronic obstructive pulmonary disease
  • 156 views
  • 18 Jul, 2021
  • 218 locations
Study to Assess the Efficacy Safety and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

itepekimab compared with placebo on Forced Expiratory Volume in 1 second (FEV1) slope in former smokers with moderate-to-severe COPD Evaluate the efficacy of itepekimab compared with placebo on

  • 0 views
  • 24 May, 2021
  • 52 locations
Study to Assess the Efficacy Safety and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)

with placebo on respiratory symptoms in former smokers with moderate-to-severe COPD Evaluate the efficacy of itepekimab compared with placebo on Forced Expiratory Volume in 1 second (FEV1

  • 0 views
  • 25 Apr, 2021
  • 21 locations